Skip to main content
GutCited
Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.
Figure 3. Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.

More Figures from This Paper

Figure 1

Figure 1

Figure 3

773 × 547px · 168,5 KB

Source Paper

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Pharmaceuticals (Basel, Switzerland) (2025)

PMID: 40006091

DOI: 10.3390/ph18020279

Cite This Figure

![Figure 3: Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.](https://pdfs.citedhealth.com/figures/40006091/231.png)

> Source: Daniela Ciobârcă et al. "Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (." *Pharmaceuticals (Basel, Switzerland)*, 2025. PMID: [40006091](https://pubmed.ncbi.nlm.nih.gov/40006091/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/40006091/231.png" alt="Figure 2. NBCs with potential therapeutic roles in T2D and MASLD." />
  <figcaption>Figure 3. Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.<br>  Source: Daniela Ciobârcă et al. "Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40006091/">40006091</a></figcaption>
</figure>

Evidencia relacionada

D
Berberine para Gut Dysbiosis

Calificación D · 2 estudios